Buy Or Sell Opportunity • 6h
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.8% to ₩79,200. The fair value is estimated to be ₩100,625, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.7% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 8.9% in the next 2 years. Buy Or Sell Opportunity • Jun 12
Now 20% overvalued Over the last 90 days, the stock has fallen 22% to ₩77,300. The fair value is estimated to be ₩64,308, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 7.7% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 8.0% in the next 2 years. Buy Or Sell Opportunity • Mar 23
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to ₩93,300. The fair value is estimated to be ₩122,935, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.6% over the last 3 years. Earnings per share has grown by 7.5%. For the next 3 years, revenue is forecast to grow by 10.0% per annum. Earnings are also forecast to grow by 14% per annum over the same time period. Reported Earnings • Mar 17
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: ₩2,599 (up from ₩943 in FY 2024). Revenue: ₩2.19t (up 5.7% from FY 2024). Net income: ₩194.1b (up 175% from FY 2024). Profit margin: 8.9% (up from 3.4% in FY 2024). Revenue missed analyst estimates by 1.8%. Earnings per share (EPS) exceeded analyst estimates by 60%. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Mar 04
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to ₩92,400. The fair value is estimated to be ₩116,764, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years. Earnings per share has declined by 3.8%. For the next 3 years, revenue is forecast to grow by 9.7% per annum. Earnings are also forecast to grow by 37% per annum over the same time period. Buy Or Sell Opportunity • Feb 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 9.5% to ₩104,400. The fair value is estimated to be ₩132,787, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.4% over the last 3 years. Earnings per share has declined by 3.8%. Revenue is forecast to grow by 24% in 2 years. Earnings are forecast to grow by 247% in the next 2 years. Buy Or Sell Opportunity • Oct 24
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.8% to ₩114,100. The fair value is estimated to be ₩143,628, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 21% in 2 years. Earnings are forecast to grow by 172% in the next 2 years. Buy Or Sell Opportunity • Aug 18
Now 20% undervalued Over the last 90 days, the stock has risen 7.8% to ₩113,700. The fair value is estimated to be ₩142,496, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years. Earnings per share has grown by 3.8%. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 195% in the next 2 years. Buy Or Sell Opportunity • Aug 01
Now 21% undervalued The stock has been flat over the last 90 days, currently trading at ₩112,700. The fair value is estimated to be ₩142,966, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years. Earnings per share has grown by 3.8%. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 198% in the next 2 years. 공고 • Jun 12
Hyung In-woo entered into a stock purchase agreement to acquire unknown additional stake in Ensol Biosciences Inc. (XKON:A140610) for KRW 14.2 billion. Hyung In-woo entered into a stock purchase agreement to acquire unknown additional stake in Ensol Biosciences Inc. (XKON:A140610) for KRW 14.2 billion on June 10, 2025. Hyung In-woo has 1,900,000 shares already held and 21.90% upon the conclusion of the contract. Number of Shares to be Sold is 810,860. The transaction is expected to complete on June 11, 2025. Price Target Changed • Mar 27
Price target increased by 8.0% to ₩150,250 Up from ₩139,083, the current price target is an average from 12 analysts. New target price is 27% above last closing price of ₩118,300. Stock is up 53% over the past year. The company is forecast to post earnings per share of ₩2,087 for next year compared to ₩898 last year. New Risk • Mar 15
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.4% net profit margin). 공고 • Feb 12
Yuhan Corporation, Annual General Meeting, Mar 20, 2025 Yuhan Corporation, Annual General Meeting, Mar 20, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 74, noryangjin-ro, dongjak-gu, seoul South Korea Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩138,400, the stock trades at a forward P/E ratio of 64x. Average forward P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 157% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩93,455 per share. Upcoming Dividend • Dec 20
Upcoming dividend of ₩429 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 31 March 2025. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%). Buy Or Sell Opportunity • Dec 10
Now 21% overvalued Over the last 90 days, the stock has fallen 2.1% to ₩117,700. The fair value is estimated to be ₩96,986, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 20% in 2 years. Earnings are forecast to grow by 35% in the next 2 years. Price Target Changed • Dec 06
Price target increased by 8.2% to ₩132,214 Up from ₩122,200, the current price target is an average from 14 analysts. New target price is 14% above last closing price of ₩115,700. Stock is up 85% over the past year. The company is forecast to post earnings per share of ₩1,716 for next year compared to ₩1,702 last year. Declared Dividend • Nov 23
Dividend of ₩429 announced Shareholders will receive a dividend of ₩429. Ex-date: 27th December 2024 Payment date: 31st March 2025 Dividend yield will be 0.4%, which is lower than the industry average of 1.1%. Price Target Changed • Sep 26
Price target increased by 8.1% to ₩110,188 Up from ₩101,941, the current price target is an average from 16 analysts. New target price is 27% below last closing price of ₩150,900. Stock is up 109% over the past year. The company is forecast to post earnings per share of ₩2,010 for next year compared to ₩1,702 last year. Price Target Changed • Sep 23
Price target increased by 7.9% to ₩108,412 Up from ₩100,471, the current price target is an average from 17 analysts. New target price is 27% below last closing price of ₩148,200. Stock is up 110% over the past year. The company is forecast to post earnings per share of ₩2,001 for next year compared to ₩1,702 last year. Valuation Update With 7 Day Price Move • Sep 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩145,900, the stock trades at a forward P/E ratio of 63x. Average forward P/E is 20x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 174% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩146,443 per share. Valuation Update With 7 Day Price Move • Aug 29
Investor sentiment improves as stock rises 44% After last week's 44% share price gain to ₩138,800, the stock trades at a forward P/E ratio of 59x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 155% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩146,517 per share. Price Target Changed • Aug 17
Price target increased by 7.1% to ₩99,222 Up from ₩92,647, the current price target is an average from 18 analysts. New target price is approximately in line with last closing price of ₩95,200. Stock is up 36% over the past year. The company is forecast to post earnings per share of ₩1,976 for next year compared to ₩1,702 last year. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩81,600, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 57% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩135,276 per share. Buy Or Sell Opportunity • Jul 31
Now 20% undervalued Over the last 90 days, the stock has risen 31% to ₩94,300. The fair value is estimated to be ₩118,428, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.7% over the last 3 years. Earnings per share has grown by 3.2%. Revenue is forecast to grow by 23% in 2 years. Earnings are forecast to grow by 77% in the next 2 years. Valuation Update With 7 Day Price Move • Jul 09
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩88,800, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 68% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩125,466 per share. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩81,900, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 48% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩105,220 per share. Major Estimate Revision • May 18
Consensus revenue estimates increase by 28% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from ₩2.08b to ₩2.67b. EPS estimate unchanged from ₩2,120 at last update. Pharmaceuticals industry in South Korea expected to see average net income growth of 16% next year. Consensus price target broadly unchanged at ₩87,419. Share price rose 8.1% to ₩77,400 over the past week. Buy Or Sell Opportunity • Apr 18
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to ₩70,300. The fair value is estimated to be ₩57,399, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has declined by 13%. For the next 3 years, revenue is forecast to grow by 6.9% per annum. Earnings are also forecast to grow by 20% per annum over the same time period. Reported Earnings • Mar 12
Full year 2023 earnings released: EPS: ₩1,815 (vs ₩1,267 in FY 2022) Full year 2023 results: EPS: ₩1,815 (up from ₩1,267 in FY 2022). Revenue: ₩1.86t (up 4.7% from FY 2022). Net income: ₩136.1b (up 43% from FY 2022). Profit margin: 7.3% (up from 5.4% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩77,200, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩89,266 per share. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Independent Outside Director Jun-Cheol Kim was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Buy Or Sell Opportunity • Jan 29
Now 21% undervalued Over the last 90 days, the stock has risen 11% to ₩60,600. The fair value is estimated to be ₩76,531, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has declined by 26%. Revenue is forecast to grow by 21% in 2 years. Earnings are forecast to grow by 115% in the next 2 years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩381 per share at 0.6% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 34% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.1%). Major Estimate Revision • Dec 05
Consensus EPS estimates increase by 37%, revenue downgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩1.95b to ₩1.91b. EPS estimate rose from ₩1,055 to ₩1,450. Net income forecast to grow 66% next year vs 31% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩87,316. Share price was steady at ₩63,300 over the past week. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to ₩61,500, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩94,605 per share. Buying Opportunity • Sep 13
Now 24% undervalued Over the last 90 days, the stock is up 25%. The fair value is estimated to be ₩97,527, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.3% over the last 3 years. Earnings per share has declined by 28%. Revenue is forecast to grow by 23% in 2 years. Earnings is forecast to grow by 138% in the next 2 years. Price Target Changed • Aug 02
Price target increased by 7.8% to ₩80,222 Up from ₩74,389, the current price target is an average from 18 analysts. New target price is 10% above last closing price of ₩72,800. Stock is up 36% over the past year. The company is forecast to post earnings per share of ₩1,489 for next year compared to ₩1,245 last year. Reported Earnings • May 20
First quarter 2023 earnings released: EPS: ₩311 (vs ₩222 in 1Q 2022) First quarter 2023 results: EPS: ₩311 (up from ₩222 in 1Q 2022). Revenue: ₩443.0b (up 7.8% from 1Q 2022). Net income: ₩22.2b (up 40% from 1Q 2022). Profit margin: 5.0% (up from 3.9% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Reported Earnings • Mar 18
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: ₩1,329 (down from ₩1,496 in FY 2021). Revenue: ₩1.78t (up 5.2% from FY 2021). Net income: ₩95.1b (down 7.3% from FY 2021). Profit margin: 5.4% (down from 6.1% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) exceeded analyst estimates by 26%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Buying Opportunity • Mar 08
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 8.4%. The fair value is estimated to be ₩65,660, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has declined by 2.9%. For the next 3 years, revenue is forecast to grow by 8.1% per annum. Earnings is also forecast to grow by 24% per annum over the same time period. Upcoming Dividend • Dec 21
Upcoming dividend of ₩381 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 03 April 2023. Payout ratio is a comfortable 35% but the company is paying out more than the cash it is generating. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%). Major Estimate Revision • Nov 09
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from ₩1.85b to ₩1.82b. EPS estimate also fell from ₩1,411 per share to ₩1,260 per share. Net income forecast to grow 16% next year vs 27% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target broadly unchanged at ₩73,825. Share price fell 4.6% to ₩57,500 over the past week. Buying Opportunity • Nov 03
Now 20% undervalued Over the last 90 days, the stock is up 1.5%. The fair value is estimated to be ₩74,333, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.7% over the last 3 years. Earnings per share has grown by 10.0%. Revenue is forecast to grow by 19% in 2 years. Earnings is forecast to grow by 55% in the next 2 years. Reported Earnings • Mar 13
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: ₩1,496 (down from ₩2,807 in FY 2020). Revenue: ₩1.69t (up 4.2% from FY 2020). Net income: ₩102.6b (down 47% from FY 2020). Profit margin: 6.1% (down from 12% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 10%, compared to a 20% growth forecast for the pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 22
Upcoming dividend of ₩381 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 04 April 2022. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 0.6%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%). Reported Earnings • Nov 18
Third quarter 2021 earnings released: EPS ₩470 (vs ₩464 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ₩451.5b (up 5.1% from 3Q 2020). Net income: ₩30.7b (up 1.0% from 3Q 2020). Profit margin: 6.8% (down from 7.1% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 23
First quarter 2021 earnings released: EPS ₩315 (vs ₩1,768 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: ₩379.0b (up 21% from 1Q 2020). Net income: ₩20.6b (down 82% from 1Q 2020). Profit margin: 5.4% (down from 37% in 1Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Apr 17
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 EPS estimate fell from ₩1,675 to ₩1,504 per share. Revenue forecast steady at ₩1.70b. Net income forecast to shrink 42% next year vs 25% growth forecast for Pharmaceuticals industry in South Korea . Consensus price target up from ₩74,507 to ₩77,833. Share price rose 6.2% to ₩67,000 over the past week. Reported Earnings • Mar 14
Full year 2020 earnings released: EPS ₩2,943 (vs ₩610 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩1.62t (up 9.4% from FY 2019). Net income: ₩192.8b (up 382% from FY 2019). Profit margin: 12% (up from 2.7% in FY 2019). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Mar 04
New 90-day low: ₩60,700 The company is down 2.0% from its price of ₩62,000 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩12,337 per share. Is New 90 Day High Low • Jan 02
New 90-day high: ₩75,100 The company is up 23% from its price of ₩61,143 on 29 September 2020. The South Korean market is also up 23% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩77,566 per share. Is New 90 Day High Low • Dec 30
New 90-day high: ₩75,100 The company is up 23% from its price of ₩61,143 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩77,566 per share. Is New 90 Day High Low • Dec 18
New 90-day high: ₩72,300 The company is up 9.0% from its price of ₩66,600 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩64,001 per share. Price Target Changed • Nov 11
Price target raised to ₩72,704 Up from ₩67,579, the current price target is an average from 14 analysts. The new target price is 13% above the current share price of ₩64,400. As of last close, the stock is up 58% over the past year. Price Target Changed • Sep 30
Price target raised to ₩67,579 Up from ₩63,148, the current price target is an average from 14 analysts. The new target price is 5.3% above the current share price of ₩64,200. As of last close, the stock is up 51% over the past year. Is New 90 Day High Low • Sep 22
New 90-day high: ₩72,000 The company is up 36% from its price of ₩53,000 on 23 June 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 32% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩19,028 per share. 
